Michael J. Overman

3 ta ish

The University of Texas MD Anderson Cancer Center

1. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

   Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.241935

2. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

   Michael J. Overman, Ray McDermott, Joseph L. Leach +13

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.241933

3. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

   Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón +15

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.630172